CXL-assisted infection reduction: a randomised clinical trial evaluating the effect of adjuvant CXL on outcomes in fungal keratitis
Prajna NV, Radhakrishnan N, Lalitha P, Austin A, Ray KJ, Keenan JD, Porco TC, Lietman TM, Rose-Nussbaumer J.
Ophthalmology 2020 Feb;127(2):159-166
Design: Randomised control trial of 403 patients with smear-positive filamentous fungal keratitis. Eyes were randomised to one of four treatment arms: (1) topical natamycin 5% alone; (2) topical natamycin 5% plus cross-linking (CXL); (3) topical amphotericin B 0.15% alone; or (4) topical amphotericin B 0.15% plus CXL.
Outcome: There was no difference in culture positivity 24 hours after commencing treatment between those randomised to amphotericin or natamycin, regardless of whether they received CXL. Those that received CXL had worse visual acuity (VA) outcomes: best corrected VA was 0.22 logMAR (2.2 Snellen lines) worse at three weeks and 0.32 logMAR (3.2 Snellen lines) worse at three months. There was no difference in infiltrate, scar size or adverse events between the groups.







